XFRA CAPITAL ADJUSTMENT INFORMATION - 03.02.2025 | Das Instrument 2E9 SE0009607252 INTERVACC AB EQUITY wird cum Kapitalmassnahme gehandelt am 03.02.2025 und ex Kapitalmassnahme am 04.02.2025 The instrument 2E9 SE0009607252 INTERVACC AB EQUITY is traded... ► Artikel lesen |
OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline | NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced... ► Artikel lesen |